Safety and Temporal Pattern of the Lymphocyte Count During Fingolimod Therapy in Patients With Multiple Sclerosis: Real-World Korean Experience
So‐Young Huh(Kosin University Gospel Hospital), Ho Jin Kim(National Cancer Center), Tai‐Seung Nam(Chonnam National University Hospital), Eun Hee Sohn(Chungnam National University), Sa‐Yoon Kang(Jeju National University), Yeon Hak Chung(Samsung Medical Center), Seong‐il Oh(Kyung Hee University), Jeeyoung Oh(Université Paris-Sud), Young‐Min Lim(Ulsan College), Kwang‐Kuk Kim(Ulsan College), Young Nam Kwon(Yonsei University), Su‐Hyun Kim(National Cancer Center), Sung‐Min Kim(Seoul National University Hospital), Nam‐Hee Kim(Korea National Institute of Health), Seung Woo Kim(Ulsan College), Ki Hoon Kim(Inje University Sanggye Paik Hospital), Jungmin So(Ulsan College), Ju‐Hong Min(Samsung Medical Center), Ha Young Shin(Yonsei University)
Cited by 5
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
|Journal of Neuroinflammation|2018|740
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
Neuromyelitis optica
|Nature Reviews Disease Primers|2020|464
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder
|Multiple Sclerosis Journal|2011|284